CClinicalTrials.gg
Status unknownNCT03086109Updated Mar 22, 2017

The Prevalence of Bone Degenerative Diseases in Beijing - a Cross-sectional Study

An observational study in Cross-sectional Study, Degenerative Disease Joint and Degenerative Disc Disease, sponsored by Beijing Jishuitan Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-22.

Sponsored by Beijing Jishuitan Hospital · Observational

The sponsor has not verified this record recently (last verified Mar 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
850
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this observational study is to investigate the prevalence and risk factors of bone degenerative diseases

02

Conditions studied

  • Cross-sectional Study
  • Degenerative Disease Joint
  • Degenerative Disc Disease

Keywords

  • prevalence
  • Bone Degenerative Disease
03

In context

Intervertebral Disc Degeneration

464 studies on the registry are indexed under Intervertebral Disc Degeneration; 98 are open to participants now.

This study's planned enrollment of 850 is above the median of 120 across 166 observational studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Beijing Jishuitan Hospital is the lead sponsor of 43 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The residents of Beijing voluntary to participant to this study

Inclusion criteria

  1. Aged 18-65 years, residents of Beijing city
  2. Must demonstrate willingness to participate in the study by signing the written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Subjects who had surgery on disc or knee
  2. Pregnent women
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
850 participants (estimated)
Patient registry
No

Interventions

  • OtherRisk factors

    Risk factors associated bone degenerative diseases

06

What researchers measure

Primary outcomes

  1. Prevalence of bone degenerative diseases

    Degree of disc and knee degeneration based on imaging examination (etc. CT OR MRI)

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Beijing Jishuitan Hospital
    Beijing, 100035, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03086109
Lead sponsor
Beijing Jishuitan Hospital
Responsible party
Wei Tian (President, Beijing Jishuitan Hospital) — Principal investigator
First posted
Mar 22, 2017
Start date
Oct 1, 2013
Primary completion
Dec 31, 2017 (estimated)
Completion
Dec 31, 2017 (estimated)
Last update
Mar 22, 2017

Study contacts

Chengai Wu, PHD
Contact
wuchengai05@163.com
+86-010-58516611
Qianqian Wang, PHD
Contact
wangqianqian84@126.com
+86-15810285282
Wei Tian, MD
study director · Beijing Jishuitan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion